Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax

Journal of General Virology

Volumn 89, Issue 12, 2008, Pages 2992-2997

  Midgley, Claire M ^a   Putz, Mike M ^a   Weber, Jonathan N ^a   Smith, Geoffrey L ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN A27; PROTEIN B5; PROTEIN H3; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; DRYVAX VACCINE; LIVE VACCINE; NYVAC VACCINE; SMALLPOX VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CELL LYSATE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETREATMENT; SEROCONVERSION; SMALLPOX; STRAIN DIFFERENCE; VACCINIA VIRUS; VIRION; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; CHO CELL; CLASSIFICATION; COMPARATIVE STUDY; CRICETULUS; HAMSTER; IMMUNOLOGY; SERODIAGNOSIS; VACCINATION; VACCINIA;

VACCINIA VIRUS; VARIOLA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEUTRALIZATION TESTS; SMALLPOX VACCINE; VACCINATION; VACCINES, ATTENUATED; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 58149386636     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.2008/004440-0     Document Type: Article

References (41)

1. Auckland, C., Cowlishaw, A., Morgan, D. & Miller, E. (2005). Reactions to small pox vaccine in naive and previously-vaccinated individuals. Vaccine 23, 4185-4187.
2. Bart, P. A., Goodall, R., Barber, T., Harari, A., Guimaraes-Walker, A., Khonkarly, M., Sheppard, N. C., Bangala, Y., Frachette, M. J. & other authors (2008). EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26, 3153-3161.
3. Bell, E., Shamim, M., Whitbeck, J. C., Sfyroera, G., Lambris, J. D. & Isaacs, S. N. (2004). Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325, 425-431.
4. Belyakov, I. M., Earl, P., Dzutsev, A., Kuznetsov, V. A., Lemon, M., Wyatt, L. S., Snyder, J. T., Ahlers, J. D., Franchini, G. & other authors (2003). Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 100, 9458-9463.
5. Benhnia, M. R., McCausland, M. M., Su, H. P., Singh, K., Hoffmann, J., Davies, D. H., Felgner, P. L., Head, S., Sette, A. & other authors (2008). Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 82, 3751-3768.
6. Boulter, E. A. & Appleyard, G. (1973). Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol 16, 86-108.
7. Davies, D. H., McCausland, M. M., Valdez, C., Huynh, D., Hernandez, J. E., Mu, Y., Hirst, S., Villarreal, L., Felgner, P. L. & Crotty, S. (2005). Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 79, 11724-11733.
8. Davies, D. H., Wyatt, L. S., Newman, F. K., Earl, P. L., Chun, S., Hernandez, J. E., Molina, D. M., Hirst, S., Moss, B. & other authors (2008). Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol 82, 652-663.
9. Edghill-Smith, Y., Venzon, D., Karpova, T., McNally, J., Nacsa, J., Tsai, W. P., Tryniszewska, E., Moniuszko, M., Manischewitz, J. & other authors (2003). Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immuno-compromised macaques. J Infect Dis 188, 1181-1191.
10. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and its Eradication. Geneva: World Health Organisation.
11. Ferrier-Rembert, A., Drillien, R., Tournier, J. N., Garin, D. & Crance, J. M. (2008). Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 26, 1794-1804.
12. Fogg, C., Lustig, S., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H. & Moss, B. (2004). Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 78, 10230-10237.
13. Frey, S. E., Newman, F. K., Yan, L., Lottenbach, K. R. & Belshe, R. B. (2003). Response to smallpox vaccine in persons immunized in the distant past. JAMA 289, 3295-3299.
14. Greenberg, R. N., Kennedy, J. S., Clanton, D. J., Plummer, E. A., Hague, L., Cruz, J., Ennis, F. A., Blackwelder, W. C. & Hopkins, R. J. (2005). Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, singlecentre, randomised controlled trial. Lancet 365, 398-409.
15. Hammarlund, E., Lewis, M.W., Hansen, S.G., Strelow, L. I., Nelson, J. A., Sexton, G. J., Hanifin, J. M. & Slifka, M. K. (2003). Duration of antiviral immunity after smallpox vaccination. Nat Med 9, 1131-1137.
16. Harari, A., Bart, P. A., Stohr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O. & other authors (2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205, 63-77.
17. Hashizume, S., Yoshizawa, H., Morita, M. & Suzuki, K. (1985). Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Listre strain. In Vaccinia Viruses as Vectors for Vaccine Antignens, pp. 87-99. New York: Elsevier Science Publishing Co.
18. Heraud, J. M., Edghill-Smith, Y., Ayala, V., Kalisz, I., Parrino, J., Kalyanaraman, V. S., Manischewitz, J., King, L. R., Hryniewicz, A. & other authors (2006). Subunit recombinant vaccine protects against monkeypox. J Immunol 177, 2552-2564.
19. Hooper, J. W., Custer, D. M., Schmaljohn, C. S. & Schmaljohn, A. L. (2000). DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266, 329-339.
20. Hooper, J. W., Custer, D. M. & Thompson, E. (2003). Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306, 181-195.
21. Hooper, J. W., Thompson, E., Wilhelmsen, C., Zimmerman, M., Ichou, M. A., Steffen, S. E., Schmaljohn, C. S., Schmaljohn, A. L. & Jahrling, P. B. (2004). Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 78, 4433-4443.
22. Kennedy, J. S., Frey, S. E., Yan, L., Rothman, A. L., Cruz, J., Newman, F. K., Orphin, L., Belshe, R. B. & Ennis, F. A. (2004). Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 190, 1286-1294.
23. Konishi, E., Kurane, I., Mason, P. W., Shope, R. E., Kanesa-Thasan, N., Smucny, J. J., Hoke, C.H., Jr & Ennis, F. A. (1998). Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates. Vaccine 16, 842-849.
24. Lai, C. F., Gong, S. C. & Esteban, M. (1991). The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. J Virol 65, 5631-5635.
25. Law, M., Pütz, M. M. & Smith, G. L. (2005). An investigetion of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model J Gen Virol 86, 991-1000.
26. Lustig, S., Fogg, C., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H. & Moss, B. (2005). Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 79, 13454-13462.
27. Mayr, A. & Munz, E. (1964). Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl Bakteriol [Orig] 195, 24-35 (in German).
28. McCormack, S., Stohr, W., Barber, T., Bart, P. A., Harari, A., Moog, C., Ciuffreda, D., Cellerai, C., Cowen, M. & other authors (2008). EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26, 3162-3174.
29. Najera, J. L., Gomez, C. E., Domingo-Gil, E., Gherardi, M. M. & Esteban, M. (2006). Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80, 6033-6047.
30. Ockenhouse, C. F., Sun, P. F., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K., Stoute, J. A., Magill, A., Krzych, U. & other authors (1998). Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177, 1664-1673.
31. Parrino, J., McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T. & other authors (2007). Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25, 1513-1525.
32. Pulford, D. J., Gates, A., Bridge, S. H., Robinson, J. H. & Ulaeto, D. (2004). Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22, 3358-3366.
33. Putz, M. M., Alberini, I., Midgley, C. M., Manini, I., Montomoli, E. & Smith, G. L. (2005). Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol 86, 2955-2960.
34. Putz, M. M., Midgley, C. M., Law, M. & Smith, G. L. (2006). Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12, 1310-1315.
35. Rivers, T. M. (1931). Cultivation of vaccinia virus for Jennerian prophylaxis in man. J Exp Med 54, 453-461.
36. Smith, G. L. & McFadden, G. (2002). Smallpox: anything to declare? Nat Rev Immunol 2, 521-527.
37. Smith, G. L., Vanderplasschen, A. & Law, M. (2002). The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83, 2915-2931.
38. Stienlauf, S., Shoresh, M., Solomon, A., Lublin-Tennenbaum, T., Atsmon, Y., Meirovich, Y. & Katz, E. (1999). Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 17, 201-204.
39. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J. C., Cox, W. I., Davis, S. W., van der Hoeven, J., Meignier, B. & other authors (1992). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
40. Treanor, J., Wu, H., Liang, H. & Topham, D. J. (2006). Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults. Vaccine 24, 6913-6923.
41. Xiao, Y., Aldaz-Carroll, L., Ortiz, A. M., Whitbeck, J. C., Alexander, E., Lou, H., Davis, H. L., Braciale, T. J., Eisenberg, R. J. & other authors (2007). A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25, 1214-1224.